KLOTHO Therapeutics (KTI™) is a biotechnology company developing a patent-pending Klotho protein that has great potential to redefine society’s experience with aging.
KTI has worldwide patents pending on versions of modified, recombinant Klotho that can be manufactured using standard cell culture technology.
LIVE WELL LONGER™
Klotho is produced naturally in the kidneys of humans and animals and has been shown to have a positive impact not only on kidney function but also diseases associated with aging. Leading researchers reported Klotho-deficient animals live 80% shorter and look older while animals overexpressing Klotho live 20-30% longer.
The company’s first focus is to improve the lives of millions of people who suffer with chronic kidney disease and acute kidney injury. Kidney disease is one of the major causes of death that affects up to 40 million people in the U.S. per year, with over 600,000 currently on dialysis. Today, there is no successful long-term therapy.
A New Era in Biotech
Multiple clinical and preclinical studies have implicated Klotho as an important anti-aging molecule regulating lifespan, health, and cognitive function. As discussed above, studies have proven that an absence of Klotho protein in laboratory animals led to a shorter lifespan and cognitive impairment. Inversely, higher circulating Klotho levels in Klotho overexpressing mice and in people carrying the KL-VS allele are associated with longer lifespan and enhanced cognitive and memory function.
There is firm evidence to support that treatment with Klotho protein or an adenovirus increases lifespan and promotes cognitive and memory function in Klotho deficient mice as well as in animal models of Alzheimer’s disease and premature aging. The cellular and molecular mechanisms of action underlying the Klotho beneficial effects on longevity and age-related cognitive decline are related to increases in cell survival, neurogenesis, neuronal maturation, modulation of glutamate signaling and LTP. Future development of Klotho therapies can revolutionize the treatment of aging and age-related cognitive decline.
Unlike traditional biotech companies in this space, KTI is minimizing the standard risks of development to reduce the cost and time of getting Klotho to human trials. Klotho Therapeutics is well positioned to enter human trials within 2 years focused on its first indication: to slow the progression of kidney disease, which affects up to 40 million patients per year in the US, 600,000 of whom are currently on dialysis. It is through this final research that true advancements in Klotho reproduction can be made.
Advantages of Klotho Protein
Aging & Cognition
Delays Diseases of Aging